Header Logo

AUNG NAING

TitleAssociate Professor
InstitutionMD Anderson
DepartmentInvestigational Cancer Therapeutics
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Taylor MH, Naing A, Powderly J, Woodard P, Chung L, Lin WH, Tian H, Siemers N, Xiang H, Deng R, Hong K, Valencia D, Huang T, Zhu Y, Liao XC, Schebye XM, Patel MR. Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2024 Nov 20; 12(11). PMID: 39567210; PMCID: PMC11580248.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Naing A, Khalil D, Rosen O, Camidge DR, Lillie T, Ji RR, Stacey A, Thomas M, Rosen L. First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. J Immunother Cancer. 2024 Oct 15; 12(10). PMID: 39414325; PMCID: PMC11481156.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    3. Campol JR, Naing AH, Aung HM, Cho SB, Kang H, Chung MY, Kim CK. Production of genetically stable and Odontoglossum ringspot virus-free Cymbidium orchid 'New True' plants via meristem-derived protocorm-like body (PLB) subcultures. Plant Methods. 2024 Sep 19; 20(1):145. PMID: 39300484; PMCID: PMC11411735.
      Citations:    
    4. Curigliano G, Curigliano H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2024 Sep 03; 30(17):3957. PMID: 39224022.
      Citations:    Fields:    
    5. Soto-Lanza F, Glick L, Chan C, Zhong L, Wilson N, Faiz S, Gandhi S, Naing A, Heymach JV, Shannon VR, Franco-Vega M, Liao Z, Lin SH, Palaskas NL, Wu J, Shroff GS, Altan M, Sheshadri A. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clin Lung Cancer. 2024 Nov; 25(7):624-633.e2. PMID: 39183094.
      Citations:    Fields:    Translation:Humans
    6. Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol. 2024 Jul 31; 8(1):166. PMID: 39085400; PMCID: PMC11291882.
      Citations:    
    7. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2024 Jul 04; 15(1):5621. PMID: 38965214; PMCID: PMC11224259.
      Citations:    Fields:    
    8. Baek S, Naing AH, Kang H, Chung MY, Kim CK. Overexpression of acdS in petunia reduces ethylene production and improves tolerance to heat stress. Plant Biol (Stuttg). 2024 Aug; 26(5):789-797. PMID: 38858861.
      Citations:    Fields:    Translation:Animals
    9. Gouda MA, Shunyakova J, Naing A, Dumbrava E, Hong DS, Yuan Y, Yang P, Myers A, Liang Y, Peng J, Karp D, Tsimberidou AM, Rodon J, Yap TA, Piha-Paul SA, Meric-Bernstam F, Fu S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open. 2024 Jun; 9(6):103486. PMID: 38914452; PMCID: PMC11258623.
      Citations:    Translation:HumansCTClinical Trials
    10. de Miguel-Perez D, Ak M, Mamindla P, Russo A, Zenkin S, Ak N, Peddagangireddy V, Lara-Mejia L, Gunasekaran M, Cardona AF, Naing A, Hirsch FR, Arrieta O, Colen RR, Rolfo C. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. J Exp Clin Cancer Res. 2024 Mar 15; 43(1):81. PMID: 38486328; PMCID: PMC10941547.
      Citations: 2     Fields:    Translation:HumansCells
    11. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387. PMID: 38126764; PMCID: PMC10860536.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    12. Adedeji OS, Naing AH, Kang H, Xu J, Chung MY, Kim CK. Editing of the ethylene biosynthesis gene in carnation using CRISPR-Cas9 ribonucleoprotein complex. Plant Methods. 2024 Feb 02; 20(1):20. PMID: 38308305; PMCID: PMC10835871.
      Citations:    
    13. Coleman N, Stephen B, Fu S, Karp D, Subbiah V, Ahnert JR, Piha-Paul SA, Wright J, Fessahaye SN, Ouyang F, Yilmaz B, Meric-Bernstam F, Naing A. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877. PMID: 38400671; PMCID: PMC10891443.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    14. Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist. 2023 Nov 02; 28(11):e1065-e1074. PMID: 37156009; PMCID: PMC10628566.
      Citations: 2     Fields:    Translation:Humans
    15. Hajjar J, Derbala MH, Naing A. Unlocking the Potential of Anti-TIGIT Therapy-Between Promise and Challenges. JAMA Oncol. 2023 11 01; 9(11):1503-1504. PMID: 37768657.
      Citations:    Fields:    
    16. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 2024 02 01; 130(3):400-409. PMID: 37864520; PMCID: PMC10841432.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    17. Aminu M, Daver N, Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol. 2023; 14:1249511. PMID: 37841255; PMCID: PMC10570510.
      Citations:    Fields:    Translation:Humans
    18. Naing AH, Baek S, Campol JR, Kang H, Kim CK. Loss of ACO4 in petunia improves abiotic stress tolerance by reducing the deleterious effects of stress-induced ethylene. Plant Physiol Biochem. 2023 Oct; 203:107998. PMID: 37678091.
      Citations:    
    19. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist. 2023 08 03; 28(8):714-721. PMID: 36952233; PMCID: PMC10400154.
      Citations: 1     Fields:    Translation:Humans
    20. Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer. 2023 08; 11(8). PMID: 37604642; PMCID: PMC10445351.
      Citations: 3     Fields:    Translation:Humans
    21. Nze C, Msaouel P, Derbala MH, Stephen B, Abonofal A, Meric-Bernstam F, Tannir NM, Naing A. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel). 2023 Jul 27; 15(15). PMID: 37568622; PMCID: PMC10417298.
      Citations: 1     
    22. Altan M, Soto F, Xu T, Wilson N, Franco-Vega MC, Simbaqueba Clavijo CA, Shannon VR, Faiz SA, Gandhi S, Lin SH, Lopez P, Zhong L, Akhmedzhanov F, Godoy MCB, Shroff GS, Wu J, Khawaja F, Kim ST, Naing A, Heymach JV, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol). 2023 10; 35(10):630-639. PMID: 37507279.
      Citations: 1     Fields:    Translation:Humans
    23. Ameri M, Al Zubidi N, Razmandi A, Whyte A, Naing A, Patel NA, Gombos DS. Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center. Cureus. 2023 Jun; 15(6):e40597. PMID: 37347077; PMCID: PMC10279808.
      Citations:    
    24. Salkeni MA, Naing A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer. 2023 09; 9(9):716-725. PMID: 37321942; PMCID: PMC10524969.
      Citations: 7     Fields:    Translation:Humans
    25. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023 09 01; 118(9):1609-1617. PMID: 37307533.
      Citations:    Fields:    Translation:HumansCells
    26. Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer. 2023 09 01; 129(17):2685-2693. PMID: 37129197.
      Citations:    Fields:    Translation:Humans
    27. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718. PMID: 37058010; PMCID: PMC10150251.
      Citations:    Fields:    Translation:Humans
    28. Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer. 2023 Dec; 54(4):1308-1315. PMID: 37119430.
      Citations:    Fields:    
    29. Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing A. Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. Br J Cancer. 2023 06; 128(12):2227-2235. PMID: 37087488; PMCID: PMC10241827.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    30. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol. 2023 Apr 18; 7(1):37. PMID: 37072571; PMCID: PMC10113233.
      Citations:    
    31. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213. PMID: 37016732.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    32. Rolfo C, Giovannetti E, Martinez P, McCue S, Naing A. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer. NPJ Precis Oncol. 2023 Mar 08; 7(1):26. PMID: 36890302; PMCID: PMC9995514.
      Citations: 5     
    33. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19. PMID: 36801912; PMCID: PMC9938883.
      Citations:    
    34. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126. PMID: 36658425.
      Citations: 28     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    35. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409. PMID: 36288393; PMCID: PMC9843435.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    36. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18. PMID: 36751659; PMCID: PMC9888522.
      Citations:    
    37. de Miguel-Perez D, Russo A, Gunasekaran M, Buemi F, Hester L, Fan X, Carter-Cooper BA, Lapidus RG, Peleg A, Arroyo-Hern?ndez M, Cardona AF, Naing A, Hirsch FR, Mack PC, Kaushal S, Serrano MJ, Adamo V, Arrieta O, Rolfo C. Baseline extracellular vesicle TGF-? is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. Cancer. 2023 02 15; 129(4):521-530. PMID: 36484171.
      Citations: 5     Fields:    Translation:HumansCells
    38. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82. PMID: 36423446; PMCID: PMC9797438.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    39. Powderly JD, Klempner SJ, Naing A, Bendell J, Garrido-Laguna I, Catenacci DVT, Taylor MH, Lee JJ, Zheng F, Zhou F, Gong X, Gowda H, Beatty GL. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study. Oncologist. 2022 11 03; 27(11):905-e848. PMID: 36156099; PMCID: PMC9632315.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    40. Naing A, Algazi AP, Falchook GS, Creelan BC, Powderly J, Rosen S, Barve M, Mettu NB, Triozzi PL, Hamm J, Zhou G, Walker C, Dong Z, Patel MR. Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors. Cancer. 2023 01 01; 129(1):71-81. PMID: 36309837; PMCID: PMC10092291.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    41. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78. PMID: 36302890; PMCID: PMC9612600.
      Citations: 1     
    42. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367. PMID: 35999229; PMCID: PMC9399082.
      Citations:    
    43. Adashek JJ, Subbiah V, Westphalen CB, Naing A, Kato S, Kurzrock R. Cancer: slaying the nine-headed Hydra. Ann Oncol. 2023 01; 34(1):61-69. PMID: 35931318; PMCID: PMC10923524.
      Citations:    
    44. How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel). 2022 Jul 29; 14(15). PMID: 35954359; PMCID: PMC9367373.
      Citations:    
    45. Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, Mennel RG, Bishop AJ, Sturgis EM, Goepfert RP, Yalamanchili S, Botello G, Stephen B, Piha-Paul SA, Patel AB, Lazar AJ, Conley AP, Benjamin RS, Patel SR, Futreal PA, Somaiah N, Naing A. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391. PMID: 35792683.
      Citations:    Fields:    
    46. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol. 2022 07; 6:e2100512. PMID: 35834760; PMCID: PMC9307306.
      Citations:    Fields:    Translation:Humans
    47. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol. 2022 Jun; 11(3):113-120. PMID: 35837373; PMCID: PMC9275440.
      Citations:    
    48. de Miguel-Perez D, Russo A, Ak M, Gunasekaran M, Mamindla P, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C, Arrieta O, Barron F, Lara-Mejia L, Cardona AF. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with?non-small cell lung cancer. J Exp Clin Cancer Res. 2022 Jun 02; 41(1):186. PMID: 35650597; PMCID: PMC9161571.
      Citations:    Fields:    Translation:HumansCells
    49. Kang H, Naing AH, Park SK, Chung MY, Kim CK. Protoplast isolation and transient gene expression in different petunia cultivars. Protoplasma. 2023 Jan; 260(1):271-280. PMID: 35622155.
      Citations:    Fields:    
    50. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701. PMID: 35610322; PMCID: PMC9130298.
      Citations:    Fields:    Translation:Humans
    51. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 05; 10(5). PMID: 35618285; PMCID: PMC9125753.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    52. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 07 15; 128(14):2736-2745. PMID: 35452134; PMCID: PMC9232977.
      Citations:    Fields:    Translation:Humans
    53. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170. PMID: 35442137.
      Citations:    Fields:    
    54. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246. PMID: 35092681; PMCID: PMC9016449.
      Citations:    Fields:    Translation:Humans
    55. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970. PMID: 35413951; PMCID: PMC9005525.
      Citations: 1     Fields:    Translation:HumansCells
    56. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A, Milton DR. Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):461. PMID: 34705134; PMCID: PMC8993725.
      Citations:    Fields:    
    57. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A, Milton DR. Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):463. PMID: 34731355; PMCID: PMC8993707.
      Citations:    Fields:    
    58. Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3). PMID: 35288468; PMCID: PMC8921936.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    59. Naing AH, Campol JR, Kang H, Xu J, Chung MY, Kim CK. Role of Ethylene Biosynthesis Genes in the Regulation of Salt Stress and Drought Stress Tolerance in Petunia. Front Plant Sci. 2022; 13:844449. PMID: 35283920; PMCID: PMC8906779.
      Citations:    
    60. Thein KZ, Fu S, Janku F, Tsimberidou AM, Piha-Paul SA, Karp DD, Shah J, Gong J, Sulovic S, McQuinn L, Stephen BA, Colen RR, Carter BW, Meric-Bernstam F, Naing A, Milton DR. Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. J Immunother Precis Oncol. 2022 Feb; 5(1):10-12. PMID: 35663832; PMCID: PMC9138422.
      Citations:    
    61. Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022 02; 10(2). PMID: 35135866; PMCID: PMC8830302.
      Citations: 3     Fields:    Translation:Humans
    62. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A, Milton DR. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol. 2021 Dec 29; 10(1):59. PMID: 34965890; PMCID: PMC8715578.
      Citations:    
    63. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021 12 10; 39(35):3978-3992. PMID: 34724386.
      Citations: 10     Fields:    Translation:Humans
    64. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 12 20; 39(36):4073-4126. PMID: 34724392.
      Citations: 34     Fields:    Translation:Humans
    65. Pant S, Moyers JT, Naing A. Letter to the editor from Pant et al. J Immunother Cancer. 2021 11; 9(11). PMID: 34725215; PMCID: PMC8562505.
      Citations:    Fields:    
    66. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A, Milton DR. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 04; 40(2):290-299. PMID: 34562230; PMCID: PMC8993773.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    67. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. 2022 02; 40(1):124-133. PMID: 34559346.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    68. Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open. 2021 10; 6(5):100230. PMID: 34479035; PMCID: PMC8414046.
      Citations: 1     Translation:Humans
    69. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24. PMID: 34362693.
      Citations:    Fields:    Translation:Humans
    70. Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591. PMID: 34241781.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    71. Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Stroh M, Hannah AL, Arkenau HT, Spira A, Gil-Martin M. CX-072 (pacmilimab), a Probody ? PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. J Immunother Cancer. 2021 07; 9(7). PMID: 34301809; PMCID: PMC8311335.
      Citations:    Fields:    Translation:Humans
    72. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Author response to Cunha et al. J Immunother Cancer. 2021 07; 9(7). PMID: 34315823; PMCID: PMC8317086.
      Citations:    Fields:    Translation:Humans
    73. Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52. PMID: 35663531; PMCID: PMC9153261.
      Citations: 3     
    74. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther. 2021; 14:3037-3049. PMID: 33994796; PMCID: PMC8114359.
      Citations: 2     Translation:CTClinical Trials
    75. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A, Milton DR. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2021 10; 39(5):1357-1365. PMID: 33909232; PMCID: PMC8542012.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    76. Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3620-3629. PMID: 33883177.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    77. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596. PMID: 33783054; PMCID: PMC8265355.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    78. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of Ocular Side Effects of Selinexor. Oncologist. 2021 07; 26(7):619-623. PMID: 33728727; PMCID: PMC8265354.
      Citations: 1     Fields:    Translation:Humans
    79. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4). PMID: 33849924; PMCID: PMC8051405.
      Citations: 9     Fields:    Translation:Humans
    80. Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 10; 39(5):1405-1410. PMID: 33770291.
      Citations: 7     Fields:    Translation:Humans
    81. Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, Kim JS, Ferry D, Drakaki A, Bendell J, Naing A. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408. PMID: 33709428; PMCID: PMC8251721.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    82. Hajjar J, Mendoza T, Zhang L, Fu S, Piha-Paul SA, Hong DS, Janku F, Karp DD, Ballhausen A, Gong J, Zarifa A, Peterson CB, Meric-Bernstam F, Jenq R, Naing A. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021 03 12; 11(1):5847. PMID: 33712647; PMCID: PMC7954807.
      Citations: 7     Fields:    Translation:HumansCells
    83. Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open. 2021 04; 6(2):100079. PMID: 33721621; PMCID: PMC7973128.
      Citations: 1     Translation:HumansCTClinical Trials
    84. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539. PMID: 33674736; PMCID: PMC8076217.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    85. Alshawa A, Cadena AP, Stephen B, Reddy A, Mendoza TR, McQuinn L, Lawhorn K, Zarifa A, Bernhardt AM, Fessaheye S, Warneke CL, Chang JY, Naing A. Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial. Invest New Drugs. 2021 08; 39(4):1113-1122. PMID: 33580845.
      Citations:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    86. Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist. 2021 07; 26(7):558-e1098. PMID: 33491277; PMCID: PMC8265349.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    87. How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep. 2021 02 11; 11(1):3667. PMID: 33574401; PMCID: PMC7878854.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    88. Williams M, Dixon K, Dupuis C, McWatters A, Avritscher R, Manrique SZ, McHugh K, Murthy R, Tam A, Naing A, Patel SP, Leach D, Hartgerink JD, Young S, Prakash P, Hwu P, Sheth RA, Mu?oz NM. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. J Immunother Cancer. 2021 02; 9(2). PMID: 33589526; PMCID: PMC7887346.
      Citations: 9     Fields:    Translation:AnimalsCells
    89. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol. 2020; 11:590494. PMID: 33552049; PMCID: PMC7859512.
      Citations: 4     Fields:    Translation:HumansCells
    90. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835. PMID: 33415580; PMCID: PMC8076052.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    91. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402. PMID: 33323389.
      Citations: 1     Fields:    Translation:Humans
    92. Cesano A, Cannarile MA, Gnjatic S, Gomes B, Guinney J, Karkada M, Kirkwood JM, Kotlan B, Masucci GV, Meeusen E, Monette A, Naing A, Tschernia N, Wang E, Wells DK, Wyant TL, Rutella S, Karanikas V, Thorsson V. Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges. J Immunother Cancer. 2020 12; 8(2). PMID: 33323463; PMCID: PMC7745522.
      Citations: 1     Fields:    Translation:Humans
    93. Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F, Hwu P. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020 12; 8(2). PMID: 33310772; PMCID: PMC7735083.
      Citations: 19     Fields:    Translation:Humans
    94. Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer. 2020 12; 8(2). PMID: 33427689; PMCID: PMC7757504.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    95. Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2021 May; 29(5):2305-2317. PMID: 33190182.
      Citations: 9     Fields:    Translation:Humans
    96. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 2020 11; 5(6):e001073. PMID: 33229506; PMCID: PMC7684827.
      Citations:    Translation:HumansCTClinical Trials
    97. Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402. PMID: 33119140.
      Citations: 1     Fields:    Translation:Humans
    98. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24. PMID: 33064988.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    99. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587. PMID: 33055173.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    100. Rutella S, Cannarile MA, Gnjatic S, Gomes B, Guinney J, Karanikas V, Karkada M, Kirkwood JM, Kotlan B, Masucci GV, Meeusen E, Monette A, Naing A, Tschernia N, Wang E, Wells DK, Wyant TL, Cesano A, Thorsson V. Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges. J Immunother Cancer. 2020 10; 8(2). PMID: 33127656; PMCID: PMC7604864.
      Citations: 5     Fields:    Translation:Humans
    101. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2). PMID: 33097611; PMCID: PMC7590372.
      Citations: 3     Fields:    Translation:Humans
    102. Choi Y, Shi Y, Haymaker CL, Naing A, Ciliberto G, Hajjar J. T-cell agonists in cancer immunotherapy. J Immunother Cancer. 2020 10; 8(2). PMID: 33020242; PMCID: PMC7537335.
      Citations: 17     Fields:    Translation:HumansCells
    103. Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192. PMID: 32910338; PMCID: PMC8944136.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    104. Rischin D, Hou JY, Cho D, Falchook GS, Formenti S, Jabbour S, Moore K, Naing A, Papadopoulos KP, Baranda J, Fury W, Feng M, Stankevich E, Li J, Yama-Dang NA, Yoo SY, Lowy I, Mathias M, Fury MG, Gil-Martin M, Gonz?lez-Martin A, Bra?a I. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 11; 159(2):322-328. PMID: 32917410.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    105. Balmanoukian AS, Infante JR, Aljumaily R, Naing A, Chintakuntlawar AV, Rizvi NA, Ross HJ, Gordon M, Mallinder PR, Elgeioushi N, Standifer N, Cann J, Durham N, Rahimian S, Kumar R, Denlinger CS, Gonz?lez-Garc?a I. Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clin Cancer Res. 2020 12 01; 26(23):6196-6203. PMID: 32887725.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    106. Kang HH, Naing AH, Kim CK. Protoplast Isolation and Shoot Regeneration from Protoplast-Derived Callus of Petunia hybrida Cv. Mirage Rose. Biology (Basel). 2020 Aug 16; 9(8). PMID: 32824283; PMCID: PMC7465674.
      Citations: 4     
    107. Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020 Aug 16; 12(8). PMID: 32824391; PMCID: PMC7465458.
      Citations: 10     
    108. Naing A, Eder JP, Piha-Paul SA, Gimmi C, Hussey E, Zhang S, Hildebrand V, Hosagrahara V, Habermehl C, Moisan J, Papadopoulos KP. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. J Immunother Cancer. 2020 08; 8(2). PMID: 32843490; PMCID: PMC7449315.
      Citations: 3     Fields:    Translation:HumansAnimalsCTClinical Trials
    109. Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7). PMID: 32630797; PMCID: PMC7408058.
      Citations: 10     
    110. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575. PMID: 32534809; PMCID: PMC7486997.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    111. Hong DS, Parikh A, Shapiro GI, Naing A, Meric-Bernstam F, Reyderman L, Binder TA, Ren M, Liu M, Dayal S, Siu AY, Sachdev P, Xu L, Bhagawati-Prasad V, Tchakov I, Ooi CE, Bao X, Varga A, Ataman ?, Marabelle A. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer. 2020 06; 8(1). PMID: 32554609; PMCID: PMC7304851.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    112. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7. PMID: 32337094; PMCID: PMC7171918.
      Citations: 5     
    113. Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing A. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1). PMID: 32303619; PMCID: PMC7204618.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    114. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172. PMID: 32127467; PMCID: PMC8386165.
      Citations: 4     Fields:    Translation:Humans
    115. Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin CC, Sharma S, Ochoa de Olza M, Varga A, Taylor M, Schellens JHM, Wu H, Sun H, Silva AP, Faris J, Mataraza J, Cameron S, Bauer TM. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020 03; 8(1). PMID: 32179633; PMCID: PMC7073791.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    116. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704; PMCID: PMC7078933.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    117. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080. PMID: 32080210; PMCID: PMC7033174.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    118. Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, Chalasani N. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. Am J Gastroenterol. 2020 02; 115(2):251-261. PMID: 31789632.
      Citations: 9     Fields:    Translation:Humans
    119. Smith DC, Kebebew E, Habra MA, Chugh R, Schneider BJ, Jafarinasabian P, Ijzerman MM, Lin VH, Mohideen P, Naing A, Kroiss M, Fassnacht M. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. 2020 10; 38(5):1421-1429. PMID: 31984451.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    120. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145. PMID: 31888672; PMCID: PMC6937824.
      Citations: 10     Fields:    Translation:Humans
    121. Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033. PMID: 31796520.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    122. George GC, Mendoza TR, Iwuanyanwu EC, Manandhar M, Afshar SF, Piha-Paul SA, Tsimberidou A, Naing A, Cleeland CS, Hong DS. Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs. 2020 08; 38(4):1166-1174. PMID: 31761957; PMCID: PMC7919140.
      Citations:    Fields:    Translation:Humans
    123. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909. PMID: 31658994; PMCID: PMC6891218.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    124. Autio KA, Boni V, Humphrey RW, Naing A. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clin Cancer Res. 2020 03 01; 26(5):984-989. PMID: 31601568; PMCID: PMC8436251.
      Citations: 37     Fields:    Translation:HumansAnimals
    125. Creasy CA, Singh G, Tapia C, Xu M, Stephen B, Sabir S, Meric-Bernstam F, Haymaker C, Bernatchez C, Naing A, Forget MA. Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. Eur J Immunol. 2019 12; 49(12):2245-2251. PMID: 31532833.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    126. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555. PMID: 31563517; PMCID: PMC8436252.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    127. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253. PMID: 31533818; PMCID: PMC6751592.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    128. Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, Achour I, Barbee S, May R, Morehouse C, Pollizzi K, Song X, Steele K, Elgeioushi N, Walcott F, Karakunnel J, LoRusso P, Weise A, Eder J, Curti B, Oberst M. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J Immunother Cancer. 2019 08 22; 7(1):225. PMID: 31439037; PMCID: PMC6704567.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    129. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158. PMID: 31445783.
      Citations:    Fields:    
    130. Naing A. A new screening tool for FGFR inhibitor treatment? Lancet Oncol. 2019 10; 20(10):1340-1342. PMID: 31405821.
      Citations: 2     Fields:    Translation:Humans
    131. Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer. 2019 05 03; 7(1):118. PMID: 31053161; PMCID: PMC6499962.
      Citations: 8     Fields:    Translation:Humans
    132. Lopez G, Salas CA, Cadiz F, Barriga C, Gonzalez P, Acevedo S, Raimilla P, Pincheira P, Naing A, Quiroga M. Complementary and Integrative Medicine Use in Individuals Seeking Conventional Medical Oncology Care in Chile: Prevalence and Patient Characteristics. J Glob Oncol. 2019 05; 5:1-6. PMID: 31095454; PMCID: PMC6550051.
      Citations: 1     Fields:    Translation:Humans
    133. Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP. Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol. 2019 02; 114(2):250-257. PMID: 30410039.
      Citations: 5     Fields:    Translation:Humans
    134. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C. Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. Am J Cardiol. 2019 04 15; 123(8):1351-1357. PMID: 30765065.
      Citations: 16     Fields:    Translation:Humans
    135. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018 11 12; 34(5):775-791.e3. PMID: 30423297; PMCID: PMC8098754.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    136. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. PMID: 30383888; PMCID: PMC6340722.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    137. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018 12; 151(3):407-413. PMID: 30366646; PMCID: PMC6281778.
      Citations: 7     Fields:    Translation:Humans
    138. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270. PMID: 30279957; PMCID: PMC6161801.
      Citations: 4     Fields:    
    139. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885. PMID: 30182147.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    140. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243. PMID: 30237864; PMCID: PMC6145698.
      Citations: 6     Fields:    
    141. Fujii T, Naing A, Rolfo C, Hajjar J. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018 Oct; 130:108-120. PMID: 30196907.
      Citations: 29     Fields:    Translation:Humans
    142. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res. 2018 08 15; 24(16):3845-3856. PMID: 30018119; PMCID: PMC6449174.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    143. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291. PMID: 29668571; PMCID: PMC6028046.
      Citations: 3     Fields:    Translation:Humans
    144. Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol. 2018 06 01; 29(6):1445-1453. PMID: 29635542; PMCID: PMC6005020.
      Citations: 36     Fields:    Translation:HumansCells
    145. Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS. Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364. PMID: 29189398; PMCID: PMC5951718.
      Citations:    Fields:    Translation:Humans
    146. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. PMID: 29695765; PMCID: PMC5988803.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    147. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141. PMID: 29748008; PMCID: PMC6204221.
      Citations: 12     Fields:    Translation:Humans
    148. Pucci M, Jantus-Lewintre E, Malarani M, Khan S, Fontana S, Naing A, Passiglia F, Raez LE, Rolfo C, Taverna S, Reclusa Asi?in P, Dur?ndez S?ez E. Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression. Target Oncol. 2018 04; 13(2):175-187. PMID: 29374391.
      Citations: 15     Fields:    Translation:HumansCells
    149. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769. PMID: 29462132; PMCID: PMC5886120.
      Citations: 7     Fields:    Translation:Humans
    150. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 06 10; 36(17):1714-1768. PMID: 29442540; PMCID: PMC6481621.
      Citations: 948     Fields:    Translation:Humans
    151. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100. PMID: 29254498; PMCID: PMC5735899.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    152. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676. PMID: 29237802; PMCID: PMC5935561.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    153. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646. PMID: 29159766; PMCID: PMC5962379.
      Citations: 58     Fields:    Translation:Humans
    154. Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607. PMID: 29075985; PMCID: PMC5924418.
      Citations: 40     Fields:    Translation:Humans
    155. Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F, M?hrmann L. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188. PMID: 29051321; PMCID: PMC5754253.
      Citations: 63     Fields:    Translation:HumansCells
    156. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMID: 29082359; PMCID: PMC5659750.
      Citations: 62     Fields:    
    157. Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93. PMID: 28810913; PMCID: PMC5557476.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    158. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173. PMID: 29152071; PMCID: PMC5675623.
      Citations:    Fields:    
    159. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162. PMID: 28729355; PMCID: PMC5902668.
      Citations: 1     Fields:    
    160. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806. PMID: 28430579; PMCID: PMC5464912.
      Citations: 4     Fields:    Translation:Humans
    161. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8). PMID: 28422758; PMCID: PMC5396533.
      Citations: 13     Fields:    
    162. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35. PMID: 28428884; PMCID: PMC5394629.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    163. Yalcin S, Hurmuz P, McQuinn L, Naing A. Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience. J Glob Oncol. 2018 09; 4:1-6. PMID: 30241173; PMCID: PMC6180833.
      Citations: 5     Fields:    Translation:Humans
    164. Porta R, Borea R, Coelho A, Khan S, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C, Ara?jo A. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Crit Rev Oncol Hematol. 2017 May; 113:256-267. PMID: 28427515.
      Citations: 82     Fields:    Translation:HumansCells
    165. Mahadevan D, Mita M, Richards D, McClay E, Heist RS, Kumar A, Sundararajan S, Naing A. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients. Cancer Chemother Pharmacol. 2017 04; 79(4):681-688. PMID: 28289865.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    166. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol. 2017 03 01; 28(3):642-650. PMID: 27993791; PMCID: PMC5834133.
      Citations: 26     Fields:    Translation:Humans
    167. Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 10; 35(5):616-626. PMID: 28194539; PMCID: PMC5935457.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    168. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143; PMCID: PMC5349913.
      Citations: 14     Fields:    Translation:Humans
    169. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444. PMID: 27882721; PMCID: PMC5224847.
      Citations: 10     Fields:    Translation:Humans
    170. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20. PMID: 27802448; PMCID: PMC5308283.
      Citations:    Fields:    Translation:Humans
    171. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215. PMID: 27599876.
      Citations: 4     Fields:    Translation:Humans
    172. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448. PMID: 27748430; PMCID: PMC5066200.
      Citations: 7     Fields:    Translation:Humans
    173. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. PMID: 27589687; PMCID: PMC5341894.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    174. Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, Hosry J, Shigle TL, Kaseb A, Torres HA. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther. 2016 12; 44(11-12):1235-1241. PMID: 27730654; PMCID: PMC5123740.
      Citations: 12     Fields:    Translation:HumansCells
    175. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569. PMID: 27528724; PMCID: PMC5657013.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    176. Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017 02; 35(1):59-67. PMID: 27687047; PMCID: PMC5896759.
      Citations: 1     Fields:    Translation:Humans
    177. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430. PMID: 27486883; PMCID: PMC5325454.
      Citations: 11     Fields:    Translation:Humans
    178. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551; PMCID: PMC5355002.
      Citations: 137     Fields:    Translation:HumansCellsCTClinical Trials
    179. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12). PMID: 27576731; PMCID: PMC5241894.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    180. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485. PMID: 27466356.
      Citations: 39     Fields:    Translation:HumansCells
    181. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409. PMID: 27412379.
      Citations: 12     Fields:    Translation:Humans
    182. Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71. PMID: 27286994.
      Citations: 3     Fields:    Translation:Humans
    183. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567; PMCID: PMC5085215.
      Citations: 6     Fields:    Translation:Humans
    184. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404. PMID: 27207774.
      Citations: 43     Fields:    Translation:HumansCells
    185. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701. PMID: 27197177.
      Citations: 109     Fields:    Translation:HumansCellsCTClinical Trials
    186. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. PMID: 26933802; PMCID: PMC5029622.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    187. Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71. PMID: 27044938; PMCID: PMC5321045.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    188. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881. PMID: 26994910.
      Citations: 1     Fields:    
    189. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7. PMID: 27014780; PMCID: PMC5978416.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    190. Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 Mar; 77(3):575-81. PMID: 26825327.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    191. Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64. PMID: 26698868.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    192. Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer. 2015; 3:51. PMID: 26674411; PMCID: PMC4678703.
      Citations: 128     Fields:    
    193. Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou A, Zinner R, Subbiah V, Hou MM, Ramirez P, Ramondetta L, Lu K, Meric-Bernstam F. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract. 2015; 2:10. PMID: 27231570; PMCID: PMC4880813.
      Citations: 5     
    194. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713. PMID: 26474549; PMCID: PMC4609167.
      Citations: 20     Fields:    Translation:Humans
    195. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. PMID: 26330075; PMCID: PMC4694960.
      Citations: 17     Fields:    Translation:Humans
    196. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. PMID: 26164085; PMCID: PMC4695071.
      Citations: 4     Fields:    Translation:Humans
    197. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. PMID: 26405159; PMCID: PMC4695208.
      Citations: 1     Fields:    
    198. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980. PMID: 26310908; PMCID: PMC4825325.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    199. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110. PMID: 26015395; PMCID: PMC4652990.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    200. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):597-603. PMID: 26210681.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    201. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10. PMID: 26169970; PMCID: PMC4840931.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    202. Bupathi M, Kaseb A, Meric-Bernstam F, Naing A. Hepatocellular carcinoma: Where there is unmet need. Mol Oncol. 2015 Oct; 9(8):1501-9. PMID: 26160430; PMCID: PMC5528787.
      Citations: 37     Fields:    Translation:HumansCells
    203. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. PMID: 26054632; PMCID: PMC4492245.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    204. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20. PMID: 25990659; PMCID: PMC4492845.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    205. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. PMID: 25980577; PMCID: PMC4494976.
      Citations: 50     Fields:    Translation:Humans
    206. Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J, Rodrigues HV. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9. PMID: 25902899.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    207. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31. PMID: 25822109; PMCID: PMC4482235.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    208. Tsimberidou AM, Said R, Culotta K, Wistuba I, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Kurzrock R, Jelinek J, Stewart DJ, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7:29. PMID: 25806091; PMCID: PMC4371799.
      Citations: 8     Fields:    
    209. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54. PMID: 25680763.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    210. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74. PMID: 25666183.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    211. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018. PMID: 25669829; PMCID: PMC6279067.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    212. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888; PMCID: PMC4291160.
      Citations: 58     Fields:    Translation:Humans
    213. Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 2015; 14(21):3434-40. PMID: 26467427; PMCID: PMC4825574.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    214. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553; PMCID: PMC4294378.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    215. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92. PMID: 25373733; PMCID: PMC4279372.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    216. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24. PMID: 25363205; PMCID: PMC4477529.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    217. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86. PMID: 25323060; PMCID: PMC4297242.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    218. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
      Citations: 41     Fields:    Translation:Humans
    219. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136; PMCID: PMC4253408.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    220. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63. PMID: 25316815.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    221. Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57. PMID: 25261369; PMCID: PMC4226703.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    222. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84. PMID: 25253784; PMCID: PMC4258414.
      Citations: 16     Fields:    Translation:HumansCells
    223. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8. PMID: 25187273; PMCID: PMC5367158.
      Citations: 132     Fields:    Translation:HumansAnimals
    224. Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock R. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One. 2014; 9(8):e93676. PMID: 25119929; PMCID: PMC4131855.
      Citations: 17     Fields:    Translation:Humans
    225. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9. PMID: 25594061; PMCID: PMC4278330.
      Citations: 9     
    226. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530. PMID: 25587555; PMCID: PMC4278323.
      Citations: 2     
    227. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. PMID: 24987059; PMCID: PMC4518867.
      Citations: 98     Fields:    Translation:Humans
    228. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. PMID: 25003695; PMCID: PMC4116527.
      Citations: 7     Fields:    Translation:Humans
    229. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12. PMID: 24919855.
      Citations: 27     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    230. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38. PMID: 24912489; PMCID: PMC4102789.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    231. Bendell JC, Hong DS, Burris HA, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):125-30. PMID: 24819685.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    232. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55. PMID: 24778042.
      Citations: 7     Fields:    Translation:Humans
    233. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22. PMID: 24764123.
      Citations: 1     Fields:    Translation:Humans
    234. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66. PMID: 24746841.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    235. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. PMID: 24752867.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    236. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55. PMID: 24742900; PMCID: PMC4039109.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    237. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8. PMID: 24668327; PMCID: PMC3983812.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    238. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388. PMID: 24586741; PMCID: PMC3929689.
      Citations: 30     Fields:    Translation:Humans
    239. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203. PMID: 24586081.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    240. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501. PMID: 24435060; PMCID: PMC4148903.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    241. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R, Luthra R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717; PMCID: PMC4409143.
      Citations: 120     Fields:    Translation:HumansCTClinical Trials
    242. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82. PMID: 24356639; PMCID: PMC3895955.
      Citations: 3     Fields:    Translation:Humans
    243. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. PMID: 25593979; PMCID: PMC4295762.
      Citations: 19     
    244. Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5. PMID: 24335388.
      Citations: 1     Fields:    Translation:Humans
    245. Abdelrahim M, Matsuda A, Naing A. TAS-106: preclinical, clinical and beyond. Oncology. 2013; 85(6):356-63. PMID: 24335431.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    246. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72. PMID: 24306314.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    247. Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014 Jun; 32(3):436-44. PMID: 24258465.
      Citations: 90     Fields:    Translation:HumansCellsCTClinical Trials
    248. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20. PMID: 24153239; PMCID: PMC3868426.
      Citations: 13     Fields:    Translation:Humans
    249. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899. PMID: 24086089; PMCID: PMC4441210.
      Citations: 90     Fields:    Translation:Humans
    250. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. PMID: 24092809; PMCID: PMC4158732.
      Citations: 18     Fields:    Translation:HumansCells
    251. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84. PMID: 24089446; PMCID: PMC3935482.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    252. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23. PMID: 24634931.
      Citations: 7     Fields:    Translation:Humans
    253. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs. 2013 Dec; 31(6):1505-13. PMID: 23982248.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    254. Hajjar J, Habra MA, Naing A. Metformin: an old drug with new potential. Expert Opin Investig Drugs. 2013 Dec; 22(12):1511-7. PMID: 23978196.
      Citations: 14     Fields:    Translation:HumansAnimals
    255. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013 Oct; 12(10):2167-75. PMID: 23963360; PMCID: PMC4138057.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    256. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. PMID: 23907406; PMCID: PMC3809091.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    257. Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle. 2013 Dec; 4(4):259-65. PMID: 23893509; PMCID: PMC3830004.
      Citations: 9     Fields:    
    258. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 01; 19(17):4824-31. PMID: 23873691; PMCID: PMC3935614.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    259. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer. 2013 Oct; 49(15):3068-75. PMID: 23867127.
      Citations: 13     Fields:    Translation:Humans
    260. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86. PMID: 23756764; PMCID: PMC5730367.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    261. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8. PMID: 23765114; PMCID: PMC3757246.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    262. Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 2013 Jun; 4(6):884-9. PMID: 23800680; PMCID: PMC3757245.
      Citations: 16     Fields:    Translation:HumansCells
    263. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    264. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. PMID: 23670029; PMCID: PMC3742831.
      Citations: 64     Fields:    Translation:Humans
    265. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84. PMID: 23800712; PMCID: PMC3742837.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    266. Naing A. Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. Expert Opin Investig Drugs. 2013 Jun; 22(6):679-85. PMID: 23631743.
      Citations: 4     Fields:    Translation:Humans
    267. Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs. 2014 Feb; 32(1):154-9. PMID: 23609829; PMCID: PMC3913855.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    268. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65. PMID: 23576709; PMCID: PMC4081655.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    269. Naing A, Kurzrock R. Dodging a dogma: is treating beyond progression beneficial? Cancer Chemother Pharmacol. 2013 May; 71(5):1385-6. PMID: 23443308.
      Citations: 2     Fields:    Translation:Humans
    270. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 05; 108(4):826-30. PMID: 23412108; PMCID: PMC3590681.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    271. Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63. PMID: 23377373; PMCID: PMC3977741.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    272. Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs. 2013 Aug; 31(4):967-73. PMID: 23361621.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    273. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555; PMCID: PMC3702215.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    274. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27. PMID: 23435217; PMCID: PMC3702212.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    275. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156; PMCID: PMC3681495.
      Citations: 47     Fields:    Translation:Humans
    276. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26. PMID: 23179336; PMCID: PMC4482128.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    277. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. PMID: 23143207.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    278. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42. PMID: 23139256; PMCID: PMC4110484.
      Citations: 10     Fields:    Translation:Humans
    279. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84. PMID: 23066039; PMCID: PMC3537862.
      Citations: 141     Fields:    Translation:HumansCells
    280. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018; PMCID: PMC4454458.
      Citations: 245     Fields:    Translation:Humans
    281. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012 Sep 25; 107(7):1093-9. PMID: 22935583; PMCID: PMC3461162.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    282. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805. PMID: 22927482.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    283. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6. PMID: 22778314.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    284. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012 Nov; 23(11):2960-2963. PMID: 22745218; PMCID: PMC4092255.
      Citations: 21     Fields:    Translation:Humans
    285. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90. PMID: 22689801; PMCID: PMC3413279.
      Citations: 38     Fields:    Translation:Humans
    286. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4. PMID: 22580643.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    287. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033. PMID: 22675430; PMCID: PMC3364990.
      Citations: 23     Fields:    Translation:HumansCells
    288. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. PMID: 22634319; PMCID: PMC4494099.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    289. Munoz J, Naing A, Qi M, Kurzrock R. Cutaneous Castleman disease. Br J Haematol. 2012 Jun; 157(6):652. PMID: 22533925.
      Citations: 2     Fields:    Translation:Humans
    290. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303. PMID: 22537607.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    291. Naing A, Ahmed J, Bahk A, Laji K. Severe autoimmune insulin resistance--a case report. QJM. 2014 Dec; 107(12):1019-21. PMID: 22499892.
      Citations:    Fields:    Translation:Humans
    292. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012 Jun; 11(6):1221-5. PMID: 22491798; PMCID: PMC3667596.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    293. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 01; 18(9):2625-31. PMID: 22465830; PMCID: PMC3875297.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    294. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9. PMID: 22452943; PMCID: PMC4176886.
      Citations: 42     Fields:    Translation:Humans
    295. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol. 2012 Aug; 23(8):1963-1967. PMID: 22377564; PMCID: PMC4092254.
      Citations: 8     Fields:    Translation:Humans
    296. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473; PMCID: PMC3295566.
      Citations: 225     Fields:    Translation:Humans
    297. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 May; 69(5):1117-26. PMID: 22205203; PMCID: PMC4091047.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    298. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806. PMID: 22039425; PMCID: PMC3198456.
      Citations: 35     Fields:    Translation:Humans
    299. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. PMID: 21890452; PMCID: PMC3207033.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    300. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8. PMID: 21859821; PMCID: PMC3228176.
      Citations: 24     Fields:    Translation:Humans
    301. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol. 2011 Sep 10; 29(26):3547-52. PMID: 21844494.
      Citations: 12     Fields:    Translation:Humans
    302. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G, Andr? V. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91. PMID: 21831956; PMCID: PMC5036398.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    303. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8. PMID: 21823111.
      Citations: 38     Fields:    Translation:Humans
    304. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508; PMCID: PMC3146490.
      Citations: 104     Fields:    Translation:Humans
    305. Ludwig JA, Lamhamedi-Cherradi SE, Lee HY, Naing A, Benjamin R. Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers (Basel). 2011 Jul 26; 3(3):3029-54. PMID: 24212944; PMCID: PMC3759185.
      Citations: 13     
    306. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60. PMID: 21750201; PMCID: PMC3176947.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    307. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther. 2011 Jul; 10(7):1300-7. PMID: 21571911.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    308. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer. 2011 Nov 15; 117(22):5142-50. PMID: 21538342.
      Citations: 27     Fields:    Translation:Humans
    309. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011 Apr 06; 6(4):e18424. PMID: 21494688; PMCID: PMC3071831.
      Citations: 38     Fields:    Translation:HumansCells
    310. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res. 2011 Jun 15; 17(12):4110-8. PMID: 21415223; PMCID: PMC3410654.
      Citations: 7     Fields:    Translation:Humans
    311. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35. PMID: 21339262; PMCID: PMC3228100.
      Citations: 4     Fields:    Translation:Humans
    312. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. J Cancer. 2011 Feb 10; 2:81-9. PMID: 21326629; PMCID: PMC3039225.
      Citations: 23     
    313. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252; PMCID: PMC3070247.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    314. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65. PMID: 21216929; PMCID: PMC3072168.
      Citations: 177     Fields:    Translation:Humans
    315. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2011 Jul; 68(1):247-53. PMID: 20941597; PMCID: PMC3410641.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    316. Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, LoRusso PM. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs. 2012 Feb; 30(1):327-34. PMID: 20842406.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    317. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 01; 117(1):77-85. PMID: 20737567; PMCID: PMC3410640.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    318. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug 01; 16(15):4031-7. PMID: 20525754.
      Citations: 5     Fields:    Translation:Humans
    319. Naing A, Kurzrock R. Chemotherapy resistance and retreatment: a dogma revisited. Clin Colorectal Cancer. 2010 Apr; 9(2):E1-4. PMID: 20378496.
      Citations: 12     Fields:    Translation:Humans
    320. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. PMID: 20347123; PMCID: PMC2882061.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    321. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1087-93. PMID: 20204368; PMCID: PMC3410638.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    322. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97. PMID: 20145187; PMCID: PMC2822881.
      Citations: 45     Fields:    Translation:Humans
    323. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2010 Feb; 10(1):46-51. PMID: 20133258.
      Citations: 5     Fields:    Translation:Humans
    324. Naing A, Aaron J, Kurzrock R. Juice plus or toxicity plus. Am J Med. 2010 Jan; 123(1):e1-2. PMID: 20102976.
      Citations: 1     Fields:    Translation:Humans
    325. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8. PMID: 19903778; PMCID: PMC2784003.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    326. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32. PMID: 19820016; PMCID: PMC2775645.
      Citations: 17     Fields:    Translation:Humans
    327. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs. 2010 Oct; 28(5):634-40. PMID: 19499186.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    328. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer. 2009 Mar 01; 115(5):1091-9. PMID: 19165805.
      Citations: 35     Fields:    Translation:Humans
    329. Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, Chang K, Slovak ML, Bhatia R, Spielberger R, Kogut N, Pullarkat V, Kirschbaum M, Forman SJ, O'Donnell MR. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant. 2007 Nov; 40(9):843-50. PMID: 17724447.
      Citations: 18     Fields:    Translation:Humans
    330. Naing A, Sokol L, List AF. Developmental therapeutics for myelodysplastic syndromes. J Natl Compr Canc Netw. 2006 Jan; 4(1):78-82. PMID: 16403406.
      Citations: 1     Fields:    Translation:Humans
    331. Naing A, Luong D, Extermann M. Methotrexate-induced status epilepticus. Am J Hematol. 2005 Sep; 80(1):35-7. PMID: 16138356.
      Citations: 2     Fields:    Translation:Humans
    332. Naing A, Messina JL, Vrionis FR, Daud AI. Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol. 2004 Aug 01; 22(15):3194-5. PMID: 15284274.
      Citations: 11     Fields:    Translation:Humans
    333. Hanutsaha P, Guyer DR, Yannuzzi LA, Naing A, Slakter JS, Sorenson JS, Spaide RF, Freund KB, Feinsod M, Orlock DA. Indocyanine-green videoangiography of drusen as a possible predictive indicator of exudative maculopathy. Ophthalmology. 1998 Sep; 105(9):1632-6. PMID: 9754169.
      Citations: 16     Fields:    Translation:Humans
    334. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 7:64421-64430.
    335. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. Journal of Clinical Oncology. 34:3562-3569.
    336. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatmentwith themammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist. 20:737-741.
    337. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clinical Cancer Research. 21:4801-4810.
    338. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 6:26886-26894.
    339. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    340. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology. 1-5.
    341. Erratum to. Cancer Chemotherapy and Pharmacology. 1.
    342. Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]. Oncotarget. 6:24581.
    343. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs. 33:621-631.
    344. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 1:540-549.
    345. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6:12809-12821.
    346. International Journal of Cancer. 140:208-215.
    347. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.
    348. Phase i study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. Journal of Clinical Oncology. 34:1764-1771.
    349. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Alimentary Pharmacology and Therapeutics. 44:1235-1241.
    350. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 7:67521-67531.
    351. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology. 78:167-171.
    352. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (Switzerland).
    353. Cancer therapy directed by comprehensive genomic profiling. Cancer Research. 76:3690-3701.
    354. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 14:3434-3440.
    355. TP53 alterations correlate with response to VEGF/VEGFR inhibitors. Molecular Cancer Therapeutics. 15:2475-2485.
    356. MET nucleotide variations and amplification in advanced ovarian cancer. Oncoscience. 1:5-13.
    357. Targets by organ site.
    358. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. Journal of Cancer. 2:81-89.
    359. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials. Investigational New Drugs. 1-9.
    360. Erratum. Cancer. 115:1588.
    361. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investigational New Drugs.
    362. Phase i study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7:1-11.
    363. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    364. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 122:3401-3409.
    365. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6.
    366. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. Journal for ImmunoTherapy of Cancer. 3.
    367. Ulnar artery thrombosis in a patient receiving emmunotherapy with interleukin-2 for metastatic renal cell carcinoma. Blood. 96.
    368. Survival of patients with metastatic leiomyosarcoma. Cancer Medicine. 5:3437-3444.
    369. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma. Oncotarget. 6:28453-28462.
    370. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.
    371. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    372. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 7:967-980.
    373. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    374. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.
    375. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults. Oncoscience. 1:522-530.
    376. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 6:20099-20110.
    NAING's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (724)
    Explore
    _
    Co-Authors (287)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _